TY - JOUR
T1 - Risk stratification of cholangiocarcinoma patients presenting with jaundice
T2 - a retrospective analysis from a tertiary referral center
AU - Lleo, Ana
AU - Colapietro, Francesca
AU - Maisonneuve, Patrick
AU - Aloise, Monia
AU - Craviotto, Vincenzo
AU - Ceriani, Roberto
AU - Rimassa, Lorenza
AU - Badalamenti, Salvatore
AU - Donadon, Matteo
AU - Pedicini, Vittorio
AU - Repici, Alessandro
AU - Di Tommaso, Luca
AU - Voza, Antonio
AU - Torzilli, Guido
AU - Aghemo, Alessio
N1 - Funding Information:
Conflicts of Interest: A.L. has consulted for Intercept Pharma, AlfaSigma, Abbvie, Gilead, and Merck Sharp and Dohme. F.C. has received speaker fees for Intercept Pharma. L.R. reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel expenses from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Roche. A.A. has received Research Grants from Abbvie and Gilead Sciences, and consulting fees from Abbvie, Gilead, MSD, Intercept Pharma, AlfaSigma, and Mylan. The other authors have nothing to disclosure. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Funding Information:
Funding: This work was partially supported by the Associazione Italiana per la Ricerca sul Cancro (IG AIRC 2019—ID 23408 to Ana Lleo) and the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds (to Patrick Maisonneuve).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Cholangiocarcinomas (CCAs) are a heterogeneous group of tumors that arise from the biliary tract. Jaundice is a common clinical presentation; however, the prognostic impact of this symptom is poorly understood, and current management recommendations lack solid evidence. We aim to assess the clinical outcomes and predictive factors of CCA patients presenting with jaundice in the Emergency Room (ER). We retrospectively analyzed all consecutive ER cases presenting with jaundice between January 2010 and December 2017. During the study period, 403,766 patients were admitted to the ER, 1217 (0.3%) presented with jaundice, and in 200 (0.049%), the diagnosis was CCA. CCA cases increased during the study period (p for trend 0.026). Most of them presented with ad-vance disease (stage III 46.5%, stage IV 43.5%) and median survival was 4.5 months (95% CI 3.4–6.0). Factors associated with better survival were age, stage of disease, presence of jaundice at the moment of diagnosis, and lack of concomitant viral hepatitis. A nomogram was constructed that significantly predicts 1-month, 6-month, and 1-year survival after patients’ admission. In conclusion, the majority of CCA patients presenting with jaundice to the ER have advanced disease and poor prognosis. Risk stratification of these patients can allow tailored management.
AB - Cholangiocarcinomas (CCAs) are a heterogeneous group of tumors that arise from the biliary tract. Jaundice is a common clinical presentation; however, the prognostic impact of this symptom is poorly understood, and current management recommendations lack solid evidence. We aim to assess the clinical outcomes and predictive factors of CCA patients presenting with jaundice in the Emergency Room (ER). We retrospectively analyzed all consecutive ER cases presenting with jaundice between January 2010 and December 2017. During the study period, 403,766 patients were admitted to the ER, 1217 (0.3%) presented with jaundice, and in 200 (0.049%), the diagnosis was CCA. CCA cases increased during the study period (p for trend 0.026). Most of them presented with ad-vance disease (stage III 46.5%, stage IV 43.5%) and median survival was 4.5 months (95% CI 3.4–6.0). Factors associated with better survival were age, stage of disease, presence of jaundice at the moment of diagnosis, and lack of concomitant viral hepatitis. A nomogram was constructed that significantly predicts 1-month, 6-month, and 1-year survival after patients’ admission. In conclusion, the majority of CCA patients presenting with jaundice to the ER have advanced disease and poor prognosis. Risk stratification of these patients can allow tailored management.
KW - Biliary drainage
KW - Cholangiocarcinoma
KW - Jaundice
UR - http://www.scopus.com/inward/record.url?scp=85104595120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104595120&partnerID=8YFLogxK
U2 - 10.3390/cancers13092070
DO - 10.3390/cancers13092070
M3 - Article
AN - SCOPUS:85104595120
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 9
M1 - 2070
ER -